[Primary HIV drug resistance in a prison population. REPRICOVA-2 Study]. / Resistencias primarias de VIH en una población penitenciaria. Estudio REPRICOVA-2.

INTRODUCTION: Currently, there are few reports on primary human immunodeficiency virus (HIV) drug resistance in the prison population. METHODS: This is a descriptive, one-day prevalence study to identify HIV drug-resistant mutations in chronically infected treatment-naïve prisoners. Systematic randomized sampling was performed and genotyping was done by automatic sequencing. RESULTS: A total of 90 patients were studied. Two samples were found to have nucleoside reverse transcriptase inhibitor (NRTI)-resistant mutations, four had non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant mutations and one had protease inhibitor (PI)-resistant mutations. CONCLUSIONS: There was a low rate of primary resistance in our series. Therefore, resistance testing is not required before prescribing initial antiretroviral therapy in these patients.

Resistencias primarias de VIH en una población penitenciaria. Estudio REPRICOVA-2 / Primary HIV drug resistance in a prison population. REPRICOVA-2 Study

INTRODUCCIÓN. Existen escasos estudios sobre resistencias primarias en pacientes presos. MÉTODOS. Estudio descriptivo, de prevalencia en un día, de mutaciones de resistencia en presos infectados crónicos nunca tratados; muestreo aleatorio sistemático. Genotipado por secuenciación automática. RESULTADOS. Se estudiaron 90 pacientes. Dos muestras tienen mutaciones de inhibidores de la transcriptasa inversa análogos de nucleósidos (ITIAN), cuatro de no nucleósidos (ITINN) y una de inhibidores de la proteasa (IP). CONCLUSIONES. Hallamos baja proporción de resistencias primarias en nuestra serie. No es necesario test de resistencias antes de la primera terapia antirretroviral (AU)

[Mutations of resistance of HIV-1 in previously untreated patients at penitentiary centers of the Autonomous Community of Valencia, Spain. REPRICOVA study]. / Mutaciones de resistencia de virus de la inmunodeficiencia humana tipo 1 en pacientes no tratados de los centros penitenciarios de la Comunidad Valenciana. Estudio REPRICOVA.

BACKGROUND: Our purpose was to determine the prevalence of mutations of resistance to nucleoside inhibitors of reverse transcriptase (NIRT) and protease inhibitors (PI) in the HIV-1 genotype of naïve infected subjects in the prisons of the Autonomous Community of Valencia, Spain. PATIENTS AND METHOD: Multicentric, descriptive, cross-sectional study of prevalence including a systematic stratified and randomised sampling by centres. Demographic, clinical, virological and immunological data were collected. The HIV gene of protease and transcriptase was studied in peripheral blood plasma samples by means of double PCR amplification and subsequent automatic sequence. Reference: wild strain HXB2. RESULTS: Plasma was obtained from 133 individuals (119 men and 14 women). 117 samples were selected and the rest did not have enough copies for transcription. With regard to NIRT, 7 samples (5.2% of total) showed some mutation of resistance: M41L, D67N, L210W and K219Q, all them secondary to and associated with resistance to zidovudine, abacavir as well as group B multinucleoside-resistance. With regard to PI, only one sample showed a primary mutation, M46I, which was associated with resistance to indinavir. Moreover, a further 41 samples were found to express some secondary mutation. CONCLUSIONS: In our series, there was a low number of primary mutations of resistance. These results allow us to exclude the systematic use of resistance tests before an initiation antiretroviral therapy.